7 research outputs found
Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN
10.1002/ajh.22069American Journal of Hematology868703-705AJHE
Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma
10.3109/10428194.2012.658792Leukemia and Lymphoma5381577-1585LELY
The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer
10.1002/ijc.27950International Journal of Cancer132122730-2737IJCN
Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma
10.1016/j.canlet.2011.03.001Cancer Letters3062161-170CALE
Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer
British Journal of Pharmacology1604998-100
Supplementary Material for: Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis
<p>Within this retrospective single-center study, we analyzed the
survival of 320 multiple myeloma (MM) patients receiving melphalan
high-dose chemotherapy (HDCT) and either single (<i>n</i> = 286) or tandem (<i>n</i>
= 34) autologous stem cell transplantation (ASCT) from 1996 to 2012.
Additionally, the impact of novel induction regimens was assessed.
Median follow-up was 67 months, median overall survival (OS) 62 months,
median progression-free survival (PFS) 33 months (95% CI 27-39), and
treatment-related death (TRD) 3%. Multivariate analysis revealed age ≥60
years (<i>p = </i>0.03) and stage 3 according to the International Staging System (<i>p = </i>0.006)
as adverse risk factors regarding PFS. Median OS was significantly
better in newly diagnosed MM patients receiving induction therapy with
novel agents, e.g., bortezomib, thalidomide, or lenalidomide, compared
with a traditional regimen (69 vs. 58 months; <i>p = </i>0.01). More
patients achieved at least a very good partial remission in the period
from 2005 to 2012 than from 1996 to 2004 (65 vs. 30%; <i>p</i> < 0.001), with a longer median OS in the later period (71 vs. 52 months, <i>p</i>
= 0.027). In conclusion, our analysis confirms HDCT-ASCT as an
effective therapeutic strategy in an unselected large myeloma patient
cohort with a low TRD rate and improved prognosis due to novel induction
strategies.</p